Thymosin α1‐ and Ulinastatin‐Based Immunomodulatory Strategy for Sepsis Arising from Intra‐Abdominal Infection Due to Carbapenem‐Resistant Bacteria
The Journal of Infectious Diseases2008Vol. 198(5), pp. 723–730
Citations Over TimeTop 20% of 2008 papers
Ying Zhang, Hao Chen, Yumin Li, Shusen Zheng, Ya‐gang Chen, Lanjuan Li, Lin Zhou, Haiyang Xie, Raaj Praseedom
Abstract
The trial was registered with the Chinese State Food and Drug Administration (Peking Science and Technology Development Plan, 2002[641]), (registration number 2007Y0211).
Related Papers
- Clinical study on treatment of continuous blood purification combined with Ulinastatin for patients with severe sepsis(2011)
- DIFERENCE OF CRP BEFORE AND AFTER ULINASTATIN TREATMENT IN THE PATIENTS WITH SEVERE ACUTE PANCREATIFIS(2012)
- Ulinastatin for treatment of 32 patients with severe acute pancreatitis(2006)
- Therapeutic Value of Ulinastatin in Pulmonary Contusion(2006)
- Study on clinical efficacy of ulinastatin in patients with acute respiratory distress syndrome(2011)